Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. Its lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and non-tuberculosis mycobacterium. The company is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis, and has tested for the prevention and treatment of inhaled bioterrorism infections, such as Coxiella burnetii or Q fever, inhalation anthrax, tularemia, melioidosis and pneumonic plague. Aradigm Corporation has collaboration agreements with Grifols, S.A. The company was founded in 1991 and is headquartered in Hayward, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARDM
CUSIPN/A
Phone510-265-9000
Debt
Debt-to-Equity Ratio-0.93
Current Ratio0.60
Quick Ratio0.60
Price-To-Earnings
Trailing P/E Ratio-2.10
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$14.47 million
Price / Sales1.59
Cash FlowN/A
Price / CashN/A
Book Value($0.83) per share
Price / Book-1.82
Profitability
EPS (Most Recent Fiscal Year)($0.72)
Net Income$-10,700,000.00
Net Margins-83.04%
Return on EquityN/A
Return on Assets-125.01%
Miscellaneous
Employees23
Outstanding Shares15,210,000
Market Cap$22.36
Aradigm (NASDAQ:ARDM) Frequently Asked Questions
What is Aradigm's stock symbol?
Aradigm trades on the NASDAQ under the ticker symbol "ARDM."
How were Aradigm's earnings last quarter?
Aradigm Co. (NASDAQ:ARDM) announced its quarterly earnings results on Tuesday, May, 15th. The company reported ($0.32) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.42) by $0.10. The business earned $1.47 million during the quarter. View Aradigm's Earnings History.
When is Aradigm's next earnings date?
What price target have analysts set for ARDM?
1 equities research analysts have issued 12 month price targets for Aradigm's stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate Aradigm's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 562.3% from the stock's current price. View Analyst Ratings for Aradigm.
What is the consensus analysts' recommendation for Aradigm?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aradigm in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
Who are some of Aradigm's key competitors?
Some companies that are related to Aradigm include Viveve Medical (VIVE), BioSig Technologies (BSGM), IRIDEX (IRIX), Soleno Therapeutics (SLNO), Stereotaxis (STXS), Digirad (DRAD), Nexeon Medsystems (NXNND), Dynatronics (DYNT), Nexeon Medsystems (NXNN), Non-Invasive Monitoring System (NIMU), CHF Solutions (CHFS), ENDRA Life Sciences (NDRA), Fc Global Realty (FCRE), Vaso (VASO) and Precision Optics (PEYE).
Who are Aradigm's key executives?
Aradigm's management team includes the folowing people:
- Dr. John M. Siebert, Exec. Chairman, Interim Principal Exec. Officer & Acting Principal Financial Officer (Age 78)
- Lisa Thomas, Corp. Controller
- Dr. David Cipolla Ph.D., VP of Preclinical R&D
Has Aradigm been receiving favorable news coverage?
News stories about ARDM stock have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aradigm earned a daily sentiment score of 0.07 on Accern's scale. They also assigned media coverage about the company an impact score of 45.68 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Aradigm's major shareholders?
How do I buy shares of Aradigm?
Shares of ARDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aradigm's stock price today?
One share of ARDM stock can currently be purchased for approximately $1.51.
How big of a company is Aradigm?
Aradigm has a market capitalization of $22.36 million and generates $14.47 million in revenue each year. The company earns $-10,700,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Aradigm employs 23 workers across the globe.
How can I contact Aradigm?
Aradigm's mailing address is 3929 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-265-9000 or via email at [email protected]
MarketBeat Community Rating for Aradigm (NASDAQ ARDM)
MarketBeat's community ratings are surveys of what our community members think about Aradigm and other stocks. Vote "Outperform" if you believe ARDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDM will underperform the S&P 500 over the long term. You may vote once every thirty days.
